© 2016 Bentham Science Publishers. In this contribution, we focused on evaluating a novel compound developed by our group. This molecule, derived from glutamine (Gln) and valproic acid (VPA), denominated (S)-5-amino-2-(heptan-4-ylamino)-5-oxopentanoic acid (Gln-VPA), was submitted to docking studies on histone deacetylase 8 (HDAC8) to explore its non-bonded interactions. The theoretical results were validated in HeLa cells as a cancer cell model and in human dermal fibroblasts as a normal cell model. The effects of Gln-VPA on HeLa and normal fibroblasts in terms of cell survival and the ability to inhibit HDAC activity in nude nuclear proteins and in nuclear proteins of whole cells treated for 24 h were analyzed. The HeLa cell cycle was analyzed after 24 and 48 h of treatment with Gln-VPA. The docking studies show that Gln-VPA can reach the catalytic site of HDAC8. Gln-VPA was organically synthesized with a purity greater than 97%, and its structure was validated using mass spectrometry, nuclear magnetic resonance and infrared spectroscopy. Gln-VPA showed a similar effect to VPA as an HDAC inhibitor but with less toxicity to fibroblasts. Although Gln-VPA was less efficient than VPA in reducing the survival of HeLa cells, it could be studied for use as a cancer cell sensitizer.
Martínez-Ramos, F., Luna-Palencia, G. R., Vásquez-Moctezuma, I., Méndez-Luna, D., Fragoso-Vázquez, M. J., Trujillo-Ferrara, J., Meraz-Ríos, M. A., Mendieta-Wejebe, J. E., & Correa-Basurto, J. (2016). Docking studies of glutamine valproic acid derivative (S)-5-amino-2-(heptan-4-ylamino)-5-oxopentanoic acid (Gln-VPA) on HDAC8 with biological evaluation in heLa cells. Anti-Cancer Agents in Medicinal Chemistry, 1485-1490. https://doi.org/10.2174/1871520616666160204111158